



Intervet Inc.
405 State Street
P.O. Box 318
Millsboro, DE 19966
(302) 934-8051

May 1, 2003

FAX RECEIVED

MAY 02 2003

GROUP 1600

TO: Examiner J. Kim
FROM: William M. Blackstone
PAGES: 3
RE: Response to Restriction Requirement
FAX: 703 308 4556
RETURN FAX: 302 934 4305

OFFICIAL

Please accept the following document in the above-identified application:

Response to Restriction Requirement of April 9, 2003 (2 pages)

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN PROPRIETARY INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT THE ADDRESSEE, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, NOTIFY US IMMEDIATELY BY TELEPHONE (COLLECT). THANK YOU.

*8/Election
w/traverse*

Attorney Docket Number O 99473 US

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

BY: David Mian
Date: 5/1/03

Bet
5-6-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

BENNINK ET AL

Serial Number: 10/031,797 Group Art Unit: 1617

Filed: October 22, 2001 Examiner: J. Kim

For: USE OF ANTI PROGESTAGENS IN COMBINED THERAPY

Corresponding to: PCT/EP00/03747, filed April 25, 2000

RESPONSE TO RESTRICTION REQUIREMENT OF APRIL 9, 2003Assistant Commissioner of Patents
Washington, D.C. 20231


May 1, 2003

Sir:

In response to the Restriction Requirement issued April 9, 2003, Applicants elect, with traverse, Group III drawn to a method of anti-progestagen therapy comprising the anti-progestagen of Formula II. The Examiner identified claims 10-18 as being within Group III. It is believed claims 2 and 4, which were not mentioned in the Office Action, should also be included within Group III as elected claims. Applicants respectfully submit that, in addition, claims 7 and 9, drawn

Attorney Docket Number O 99473 US
to methods of contraception, should be included in Group III
drawn to methods of anit-progestagen therapy as well.
Similarly, claim 8 should be included as it is also a method
of anti-progestagen therapy. It is further submitted that, as
it would not appear to engender any additional hardship to
search or examine them, claims 5 and 6 to the combined dosage
unit and the contraceptive kit comprising a dosage unit of Org
33245 should be examined in the present application as well.

Respectfully submitted,



William M. Blackstone
Attorney for Applicants
Registration No. 29,772

Akzo Nobel Patent Department
Intervet Inc
405 State Street
P.O. Box 318
Millsboro, DE 19966
Tel: (410) 464-0581
Sec: (302) 933-4027
Fax: (302) 934-4305